GlassScriptPhysician profile
Katelyn B Watkins
NPI 1326747940
$2,105.01
in general payments reported to CMS, 2019-2025
16 companies · $842 in 2025
The $842 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $98.19 · 2024: $1,165 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $438.16 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $254.48 | 2024-2025 | |
| Amgen INC. | $178.58 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $98.87 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $90.09 | 2024-2025 | |
| Esperion Therapeutics, INC. | $89.36 | 2024-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.69 | 2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $72.22 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biotissue Holdings INC. | $45.08 | 2024 | |
| Exact Sciences Corporation | $38.74 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $31.02 | 2024 | Voquezna |
| Soleno Therapeutics, INC. | $26.95 | 2025 | Vykat Xr |
| Otsuka America Pharmaceutical, INC. | $20.48 | 2024 | Rexulti |
| Abbott Laboratories | $19.35 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.08 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.